Abstract Number: 2791 • 2019 ACR/ARP Annual Meeting
Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review
Background/Purpose: A comprehensive assessment of outcome measures to assess response to treatment in ANCA-associated vasculitis (AAV) is necessary to implement.Methods: We performed a scoping review…Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…Abstract Number: 1745 • 2019 ACR/ARP Annual Meeting
Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare primary systemic vasculitis that affects aorta and its major branches. This condition is associated with reduced wall…Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting
Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…Abstract Number: 1667 • 2019 ACR/ARP Annual Meeting
Long Term Outcome of Hydralazine-Associated Vasculitis
Background/Purpose: Hydralazine associated vasculitis (HAV) is rare but with potentially detrimental complications, affecting different organ systems. Most case series described short term disease course. Hence,…Abstract Number: 1747 • 2019 ACR/ARP Annual Meeting
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Background/Purpose: Renal disease is common in ANCA-associated vasculitis (AAV) and one of the goals of early treatment is to maximize renal function recovery. Corticosteroids are…Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…Abstract Number: 2104 • 2019 ACR/ARP Annual Meeting
Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Background/Purpose: A large spectrum of vasculitides affecting small, medium, and large vessels have been reported in HIV-infected individuals. Although vasculitis is a rare manifestation of…Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…Abstract Number: 312 • 2019 ACR/ARP Annual Meeting
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- 35
- Next Page »